Why You Can Expect Extra Volatility From Gilead Sciences, Inc. This Year

Sovaldi might be first on the market, but competition is fierce and the stakes are high.

Feb 12, 2014 at 6:30PM

When Gilead Sciences (NASDAQ:GILD) reported fourth quarter earnings after the market closed on February 4, a lack of guidance for Sovaldi hit a nerve. Despite a great year, and plenty of reasons to expect better times ahead, shares slumped the following day. Here's a look at how the actions of pharmacy benefit managers like Express Scripts (NASDAQ:ESRX), and competition from Bristol-Myers Squibb, Merck (NYSE:MRK), and AbbVie (NYSE:ABBV) are likely to keep Gilead's (NASDAQ:GILD) stock price on a roller coaster for the rest of the year.

Operation estimate
With less than a month on the US market, Gilead (NASDAQ:GILD) recorded over $139 million in Sovaldi sales during fourth quarter of 2013. Patient demand accounted for about $50 million. Filling the inventories of wholesalers added nearly $70 million, and a one time order for for a clinical trial from an unnamed customer tacked on $15 million.

Now, that's a pretty big month, but don't even bother annualizing that figure to estimate this year's total. Government and commercial payers take time to add new drugs to their formulary, even ones as important as Sovaldi. With a price tag of over $80,000 per patient for a 90-day supply, some foot dragging should be expected.

During the earnings call, management claimed the drug was given a higher copay tier typical of new specialist drugs. Gilead (NASDAQ:GILD) has a patient assistance program that, when allowed, will use foundation grants to help patients meet copay amounts. It's not unheard of for companies to fund their own foundations, then use them to help patients meet their copays.

The important takeaway here is that estimating sales for a drug like Sovaldi this early into its launch involves a great deal of guesswork. Just how much of an impact copay amounts and assistance programs will make is one of many unknowns factored into sales estimates.

Gilead (NASDAQ:GILD) management did provide a 2014 total sales range of between $11.3 billion and $11.5 billion, excluding Sovaldi, which is a fairly impressive increase of about 7% from 2013. If you include the average estimate of about $5 billion for Sovaldi sales this year, that's a one-year topline increase of over 50%. It's not hard to see why this stock doubled in 2013.

A drugmaker's nightmare
Copay amounts are important, but here's the biggest reason you can expect Gilead (NASDAQ:GILD) sales estimates to vary from week to week this year. Pharmacy benefit manager Express Scripts (NASDAQ:ESRX) intends to force pharmaceutical companies like Gilead (NASDAQ:GILD) and AbbVie (NYSE:ABBV) to compete on price for drugs that provide similar benefit. This sounds like a fair proposition, until you consider the consequences of losing, even by a little. Being left off a major formulary could easily bite a double-digit percent sized chunk from sales and send the stock price reeling.

Before forcing companies to compete, Express Scripts (NASDAQ:ESRX) has made it clear that their products' clinical benefit must be similar. Given the data available, it looks like nail biting time.

Couldn't be much closer
In December of last year, Gilead (NASDAQ:GILD) posted some outstanding phase 3 data for Sovaldi and its NS5A inhibitor ledipasvir combo treatment for patients with chronic genotype 1 (GT1) hepatitis C virus (HCV). The studies included a variety of patients with and without cirrhosis. Some had experienced previous treatment, and some hadn't. Of 1,518 patients, 95.9% showed a 12-week sustained virological response (12SVR). More impressive was a group of 109 treatment-experienced patients within the study that showed a 93.6% SVR12.

It looks like we'll get to see if Express Scripts (NASDAQ:ESRX) is serious about price competition for therapies with similar benefit. At the end of January, AbbVie (NYSE:ABBV) released results from phase 3 studies of its all-oral combination therapy. Like the Sovaldi/ledipasvir combination trials, these patients also suffered from GT1 HCV. Overall, 2053 patients showed a 96% SVR12. One treatment-experienced arm containing 91 GT1b patients showed a 100% SVR12.

More fun to come
Far behind AbbVie (NYSE:ABBV) and Gilead (NASDAQ:GILD), Merck (NYSE:MRK) has a two-pill HCV combo that looks like it could be equally effective. In November of last year, the company released data from a 65-patient phase 2 study. All 11 patients in the ribavirin arm with 12-week data showed a sustained virological response. You definitely want to keep an eye open for phase 3 data from this combo.

Bristol-Myers looks like it might compete with the other half of Gilead's (NASDAQ:GILD) HCV combination with its own NS5A inhibitor, daclatasvir. In a study last month that included 41 patients who did not respond to other HCV protease inhibitors, the Sovaldi/daclatasvir combo raised some eyebrows with a SVR12 of 98%. Gilead (NASDAQ:GILD) intends to market its two-drug regimen as a single pill, so this could lead to all sorts of complications.

Final thoughts
If Express Scripts (NASDAQ:ESRX) makes good on its threat, it's hard to say just how low AbbVie (NYSE:ABBV) and Gilead (NASDAQ:GILD) will go to remain on the formulary. In Europe, Gilead (NASDAQ:GILD) has already succomed to pressure from payers. The 12-week treatment that runs $84,000 in the US, will go for $66,000 in Germany and $57,000 in the UK.

For Gilead's (NASDAQ:GILD) long-term investors, the important thing to remember here is that management's topline growth estimate of 6-8% excluding Sovaldi is impressive on its own. Although things might get very bumpy this year, that's hardly a reason to let go now.

Here are three more stocks to hold on to
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 

Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Express Scripts and Gilead Sciences. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers